news
G-CSF protein involved in cocaine addiction
Researchers have identified a protein produced by the immune system that could be responsible for the development of cocaine addiction...
List view / Grid view
Hit-to-Lead
news
Blood-vessel-on-a-chip provides insight into new anti-inflammatory drug candidate
Researchers have discovered that synthetic APC-mimicking molecules provide anti-inflammatory and anti-thrombotic protection to endothelial cells without interfering with blood clotting...
news
Hear from Janssen and Antikor Biopharma at SMi’s ADC Conference, April 2018
SMi's ADC conference will be bringing a global presence from Pfizer, Genentech, Ablynx, Spirogen, Seattle Genetics, Medimmune, Antikor Biopharma, Heidelberg Pharma and more...
news
Researchers use AI technology to chart immune cell receptor
Johns Hopkins scientists have used a form of artificial intelligence to create a map that compares types of cellular receptors, the chemical ‘antennas’ on the surface of immune system T-cells.
news
Anti-obesity drug shrinks fat without suppressing appetite
Researchers have discovered a drug that has been shown to selectively shrink excess fat by increasing fat cell metabolism...
article
Rational drug design: How far have we come?
From the early use of Hansch parameters and Topliss Trees to today’s computational structure–activity techniques, medicinal chemists have long sought to rationalise drug design to find the quickest and most resource-efficient route to market. But while modern strategies are more reliant on statistical algorithms and vast data libraries, these founding…
news
Organ-on-a-chip device successfully models heart disease
A new device that models atherosclerosis can help researchers better understand the disease, develop therapies and diagnose blood health...
article
Expert view: Conquering late stage failures with advanced hit-to-lead techniques
Failing early in drug discovery is the primary driving force for new techniques in the hit-to-lead phase.
article
Identification of hits and leads for human African trypanosomiasis
Neglected tropical diseases (NTD) affect more than one billion people and new targets and drugs are needed to tackle these infections. The multi-disciplinary NMTrypI consortium has identified a number of different compound classes which could be effective against these diseases. This article reviews some of these compounds...
article
Expert view: Optimising the hit-to-lead workflow
Hits identified in high-throughput screens are evaluated within the hit-to-lead phase of drug discovery, where they undergo an iterative optimisation process employing a variety of techniques to identify promising lead compounds to move forward to the lead optimisation phase.
article
A pragmatic approach to hit validation following biochemical high-throughput screening
Progressing actives from a high-throughput screen (HTS) of a target protein into suitable starting points for lead identification is fraught with pitfalls. The volume and quality of the HTS output is a function of the quality of the screening library, as well as specific properties of both the target and…
news
IONIS-HTTRx lowers deadly Huntington’s disease protein
The first drug targeting the cause of Huntington’s disease was safe and well-tolerated in its first human trial…
article
Meeting access challenges with adaptive trial designs
With access challenges even after successful but costly development programmes, the industry is under pressure to speed up the clinical development process and produce more for less. Adaptive trial designs, more collaborative working and data sharing could provide a solution in the area of cancer immunotherapy, says Jacqueline Karmel, principal…
article
Expert view: Improving hit-to-lead results
Declining R&D productivity is a key challenge in the pharmaceutical industry today.
news
Novel compound restores immune response in patients with melanoma
A novel compound may restore immune response in patients with melanoma, according to a study presented at the ESMO Immuno Oncology Congress 2017.1
